SCHEMBL6998631

SCHEMBL6998631

Cc1cc(C(=O)Nc2cc(Cl)ccc2O)c(Br)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 15/20 0.61
KDM4E B2RXH2 2/20 0.53
HIF1A Q16665 1/20 0.53
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
TP53 P04637 2/20 0.50
KMT2A Q03164 2/20 0.50
USP2 O75604 1/20 0.50
GAA P10253 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
F12 P00748 1/20 0.49
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
RAB9A P51151 2/20 0.47
POLB P06746 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7654114 0.90 CXCR2 (0.51) KCNMA1KDM4EMAPTKMT2AF12
SCHEMBL6991334 0.86 KCNMA1 (0.57) KCNMA1MAPTMEN1TP53KMT2A
SCHEMBL6996991 0.84 KCNMA1 (0.52) KCNMA1KDM4EHIF1AMAPTMEN1
SCHEMBL6997403 0.82 NPC1 (0.55) KCNMA1KDM4EMAPTMEN1TP53
SCHEMBL7658670 0.80 KCNMA1 (0.60) KCNMA1HIF1AMAPTMEN1TP53
SCHEMBL7664623 0.78 KCNMA1 (0.64) KCNMA1KDM4EHIF1AMAPTMEN1
SCHEMBL6995125 0.78 RAB9A (0.53) KCNMA1MAPTMEN1KMT2AGAA
SCHEMBL7661723 0.76 HDAC1 (0.43) KCNMA1KDM4EMAPTMEN1KMT2A
SCHEMBL7666549 0.75 MAPT (0.49) KCNMA1KDM4EMAPTTP53KMT2A
SCHEMBL7665120 0.74 MAPT (0.50) MAPTMEN1TP53KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
CN-1268949-A Fused thiophene compounds and medical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2000-10-04 CN disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT KCNMA1 2043/4885KDM4E 3066/4885HIF1A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.